Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 3/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21205920 | 1.00 | GABRR1 (0.32) | GABRR1GABBR1LMNA | |
| SCHEMBL24549452 | 1.00 | GABRR1 (0.32) | GABRR1GABBR1LMNA | |
| SCHEMBL13370520 | 0.78 | GABBR1 (0.31) | GABBR1 | |
| SCHEMBL22000910 | 0.74 | LMNA (0.31) | LMNA | |
| SCHEMBL17886581 | 0.74 | LMNA (0.34) | LMNA | |
| SCHEMBL24549460 | 0.71 | CYP1A2 (0.30) | — | |
| SCHEMBL22648471 | 0.71 | CYP1A2 (0.30) | — | |
| SCHEMBL24783009 | 0.71 | LMNA (0.40) | LMNA | |
| SCHEMBL24549456 | 0.71 | CYP1A2 (0.30) | — | |
| SCHEMBL13734046 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN2, ERN1 | GABRR1 4684/4885GABBR1 4772/4885LMNA 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.